What is NAFLD
& NASH?
Are you at risk?
In adults over 50 years of age, 1 in 3 will have some form of fatty liver disease, and greater than half of all patients with Type II diabetes develop NAFLD or NASH.
![shutterstock_1924790111 (1) [Converted].png](https://static.wixstatic.com/media/0c4ee5_6478673327b94c9997a64e7cfcf05c66~mv2.png/v1/fill/w_848,h_408,al_c,q_85,usm_0.66_1.00_0.01,enc_avif,quality_auto/shutterstock_1924790111%20(1)%20%5BConverted%5D.png)
NASH patients typically do not show symptoms.
Non-invasive tests can be performed to assess a patient for potential NASH:
-
FibroScan
-
Blood-based scores (FIB-4, NAFLD score)
​
Currently there are no FDA approved therapies to prevent or treat NASH.
Several clinical research studies for developing treatments are available.
​
Contact DRI today to see if a clinical trial is right for you.
​
NASH has more than doubled in the last 20 years due to the epidemic of diabetes and obesity, in link with unhealthy lifestyle (fatty foods, excess carbohydrates, drinks rich in sugar/fructose).
Non-Alcoholic Fatty Liver Disease (NAFLD) is often a silent condition where the liver becomes infiltrated with fat (steatosis), causing dysfunction at a cellular level.
​
Non-Alcoholic Steatohepatitis (NASH) is defined as the presence of hepatic steatosis and inflammation, with or without fibrosis or scarring. NASH is a progressive condition and without intervention can lead to cirrhosis, liver cancer, and ultimately to liver failure.
Risk Factors and Clinical Cues
Prediabetes or Type II Diabetes
Obesity
BMI > 30
Hypertension
50 Years of Age
or Older
High
Cholesterol
High
Triglycerides
![shutterstock_1851955240 [Converted].png](https://static.wixstatic.com/media/0c4ee5_0edfa2c395dc4c17a4dc5bcddfa7eb00~mv2.png/v1/fill/w_600,h_400,al_c,q_85,usm_0.66_1.00_0.01,enc_avif,quality_auto/shutterstock_1851955240%20%5BConverted%5D.png)